Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...
Verywell Health on MSN
DMT treatment options for multiple sclerosis
Disease-Modifying Therapy Comparison and Side Effects ...
The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...
In 2014, the European Medicines Agency approved the drug Tecfidera for the treatment of relapsing multiple sclerosis, a neurodegenerative disease that affects millions of people worldwide. In multiple ...
The European Commission gave its stamp of approval for Vumerity (diroximel fumarate), developed by Biogen, as an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS). The ...
Biogen BIIB announced that the European Commission (EC) has approved its marketing authorization application for its next-generation, oral multiple sclerosis drug, Vumerity (diroximel fumarate) for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results